End-of-day quote
Shenzhen S.E.
03:30:00 31/05/2024 am IST
|
5-day change
|
1st Jan Change
|
9.2
CNY
|
+0.88%
|
|
-6.88%
|
-4.47%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,350
|
1,689
|
1,571
|
1,981
|
1,636
|
2,327
|
Enterprise Value (EV)
1 |
1,490
|
1,894
|
1,688
|
2,103
|
1,661
|
2,461
|
P/E ratio
|
216
x
|
319
x
|
-5.6
x
|
-21.7
x
|
-13.5
x
|
92.3
x
|
Yield
|
0.31%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.19
x
|
1.49
x
|
1.85
x
|
2.13
x
|
1.97
x
|
2.91
x
|
EV / Revenue
|
1.31
x
|
1.67
x
|
1.99
x
|
2.26
x
|
2
x
|
3.08
x
|
EV / EBITDA
|
15.8
x
|
84.5
x
|
-12.5
x
|
60.4
x
|
48.7
x
|
31.9
x
|
EV / FCF
|
-75.4
x
|
-106
x
|
100
x
|
90.8
x
|
5.25
x
|
-12.2
x
|
FCF Yield
|
-1.33%
|
-0.94%
|
1%
|
1.1%
|
19.1%
|
-8.2%
|
Price to Book
|
1.69
x
|
2.07
x
|
2.29
x
|
3.36
x
|
2.85
x
|
3.88
x
|
Nbr of stocks (in thousands)
|
2,08,308
|
2,08,308
|
2,27,971
|
2,27,971
|
2,41,619
|
2,41,619
|
Reference price
2 |
6.480
|
8.110
|
6.890
|
8.690
|
6.770
|
9.630
|
Announcement Date
|
26/04/19
|
27/04/20
|
26/04/21
|
28/04/22
|
24/04/23
|
18/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,136
|
1,132
|
848.1
|
930.4
|
829
|
799.3
|
EBITDA
1 |
94.14
|
22.41
|
-135.4
|
34.84
|
34.08
|
77.24
|
EBIT
1 |
39.69
|
-28.12
|
-198.3
|
-28.16
|
-23.64
|
25.1
|
Operating Margin
|
3.49%
|
-2.48%
|
-23.39%
|
-3.03%
|
-2.85%
|
3.14%
|
Earnings before Tax (EBT)
1 |
14.77
|
1.894
|
-298.4
|
-65.48
|
-90.02
|
55.28
|
Net income
1 |
7.241
|
5.297
|
-262.4
|
-91.44
|
-118.6
|
25.2
|
Net margin
|
0.64%
|
0.47%
|
-30.94%
|
-9.83%
|
-14.3%
|
3.15%
|
EPS
2 |
0.0300
|
0.0254
|
-1.230
|
-0.4011
|
-0.5002
|
0.1043
|
Free Cash Flow
1 |
-19.75
|
-17.79
|
16.84
|
23.16
|
316.6
|
-201.7
|
FCF margin
|
-1.74%
|
-1.57%
|
1.99%
|
2.49%
|
38.19%
|
-25.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
66.46%
|
929.01%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0200
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/04/19
|
27/04/20
|
26/04/21
|
28/04/22
|
24/04/23
|
18/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
140
|
204
|
118
|
122
|
25
|
135
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.488
x
|
9.118
x
|
-0.8677
x
|
3.511
x
|
0.7327
x
|
1.742
x
|
Free Cash Flow
1 |
-19.8
|
-17.8
|
16.8
|
23.2
|
317
|
-202
|
ROE (net income / shareholders' equity)
|
1.03%
|
-0.19%
|
-31.1%
|
-9.22%
|
-13.3%
|
6.46%
|
ROA (Net income/ Total Assets)
|
1.65%
|
-1.07%
|
-6.88%
|
-1.06%
|
-0.95%
|
1.04%
|
Assets
1 |
440
|
-497
|
3,813
|
8,642
|
12,484
|
2,423
|
Book Value Per Share
2 |
3.840
|
3.920
|
3.010
|
2.590
|
2.380
|
2.480
|
Cash Flow per Share
2 |
0.7100
|
0.6900
|
0.8300
|
0.4700
|
1.090
|
0.5500
|
Capex
1 |
29.6
|
18.5
|
31.5
|
36.9
|
26.8
|
33.9
|
Capex / Sales
|
2.6%
|
1.64%
|
3.71%
|
3.97%
|
3.23%
|
4.24%
|
Announcement Date
|
26/04/19
|
27/04/20
|
26/04/21
|
28/04/22
|
24/04/23
|
18/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.47% | 307M | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | +9.78% | 210B | | -5.52% | 206B | | +6.17% | 164B |
Other Pharmaceuticals
|